OCEANSIDE, CA–(Marketwired – July 11, 2016) – Therapeutic Solutions International, Inc., (OTC PINK: TSOI) reported novel data supporting the use of pterostilbene, a natural analog of resveratrol with greater bioavailability, as an adjuvant to immunotherapy of cancer in a murine melanoma model. The reported data, which is part of the Company’s filed Utility Patent #15/204560, demonstrated a synergy of inhibiting melanoma growth between pterostilbene and a T cell activating a FDA approved immunotherapeutic, as well as augmentation of immune stimulating cytokines. Cytokines are molecular signals the immune system uses to coordinate attacks on pathogenic invaders as well as cancer cells.
Inventors on the patent are Thomas Ichim, Ph.D., Timothy Dixon, Robert Graham, Gerry Berg, and Santosh Kesari, MD, Ph.D. The patent covers various combinations of pterostilbene with immunotherapeutics for the purpose of augmenting efficacy in both the stimulation of immune killer cells, as well as immune cells that reduce growth of cancer cells.
“Although immunotherapeutics of cancer is a rapidly evolving field, these approaches induce various biochemical manipulations of the body, which in many cases cause nutrient and oxidative dis-balances. We believe that administration of pterostilbene effectively restores dis-balances caused by immunotherapy, thus resulting in enhanced efficacy,” said Timothy Dixon, President and CEO of Therapeutic Solutions International.
Pterostilbene is the star ingredient of ProJuvenol©, a nutraceutical currently sold by the Company and available online at www.youcanordernow.com. ProJuvenol© is a powerful synergistic blend of complex anti-aging ingredients inspired by nature to help promote cellular rejuvenation and healthy functionality for everyday living, based in pterostilbene, one of nature’s unique and intelligent antioxidants/anti-inflammatories.
“We are thankful for our academic collaborators who have generated this new and exciting data. We are in the process of performing additional experiments and hope to publish these data in the peer-reviewed literature in the near future,” said Thomas Ichim, Ph.D., Board Member of TSOI. “Examples of immunotherapeutics that would be enhanced by pterostilbene, if the data we reported is extrapolatable to humans, include Herceptin, Rituximab, and Cetuximab,” added Dr. Ichim.
About Therapeutic Solutions International, Inc.
The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.